Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

CERS

Cerus Corp

Jun 06 • 04:00PM ET

1.51

Dollar change +0.13
Percentage change 9.42	%

Healthcare • Medical Devices • USA • NASD

Peers: QDEL BIO HCSG AEMD ARWR AXDX MMSI FATE INSP XERS

| Held by: ARKK ARKG VTI IWM VXF IWO SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.10	Insider Own	6.51%	Shs Outstand	191.11M	Perf Week	18.90%
Market Cap	288.65M	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-6.53%	Shs Float	178.71M	Perf Month	16.15%
Income	-18.95M	PEG	-	EPS next Q	-0.03	Inst Own	75.51%	Short Float	4.94%	Perf Quarter	0.00%
Sales	185.14M	P/S	1.56	EPS this Y	4.55%	Inst Trans	2.42%	Short Ratio	6.62	Perf Half Y	-14.69%
Book/sh	0.29	P/B	5.20	EPS next Y	64.29%	ROA	-9.57%	Short Interest	8.84M	Perf Year	-16.11%
Cash/sh	0.42	P/C	3.57	EPS next 5Y	-	ROE	-36.14%	52W Range	1.12 - 2.54	Perf YTD	-1.95%
Dividend Est.	-	P/FCF	43.02	EPS past 5Y	25.97%	ROI	-14.32%	52W High	-40.55%	Beta	1.54
Dividend TTM	-	Quick Ratio	1.63	Sales past 5Y	13.96%	Gross Margin	56.00%	52W Low	34.82%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	2.32	EPS Y/Y TTM	41.50%	Oper. Margin	-18.22%	RSI (14)	64.17	Volatility	6.57% 4.31%
Employees	281	Debt/Eq	1.79	Sales Y/Y TTM	13.06%	Profit Margin	-10.23%	Recom	1.50	Target Price	4.67
Option/Short	Yes / Yes	LT Debt/Eq	1.38	EPS Q/Q	22.56%	Payout	-	Rel Volume	3.25	Prev Close	1.38
Sales Surprise	-1.44%	EPS Surprise	0.00%	Sales Q/Q	12.70%	Earnings	May 01 AMC	Avg Volume	1.33M	Price	1.51
SMA20	14.63%	SMA50	13.90%	SMA200	-8.94%	Trades		Volume	4,340,611	Change	9.42%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	Craig Hallum	Buy	$5
Jan-20-23	Downgrade	BTIG Research	Buy → Neutral
Jan-17-23	Downgrade	Stephens	Overweight → Equal-Weight	$3.75
Oct-08-20	Resumed	BTIG Research	Buy	$9
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$9
Feb-26-20	Initiated	BTIG Research	Buy	$7
Nov-13-19	Upgrade	BTIG Research	Neutral → Buy	$7
Aug-28-19	Initiated	Stifel	Buy
Aug-23-19	Resumed	Stephens	Overweight
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Dec-08-17	Resumed	BTIG Research	Neutral
Jul-07-16	Resumed	Cantor Fitzgerald	Buy	$9
Dec-17-15	Downgrade	Wedbush	Outperform → Neutral
May-02-14	Reiterated	MLV & Co	Buy	$8.50 → $6
Apr-24-13	Reiterated	Cantor Fitzgerald	Buy	$5.50 → $6
Mar-15-13	Reiterated	MLV & Co	Buy	$7.50 → $8.50
Apr-17-12	Initiated	Cantor Fitzgerald	Buy	$5.50
Feb-29-12	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $6
Nov-10-11	Reiterated	MLV & Co	Buy	$4 → $5
Jun-03-11	Initiated	Wedbush	Outperform	$4

Show Previous Ratings

Jun-03-25 04:30PM	Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.09%
May-29-25 08:30AM	Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan (Business Wire)
May-28-25 08:30AM	Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 Next-Generation INTERCEPT Illumination Device (Business Wire)
May-01-25 08:26PM	Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:05PM	Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Loading…
04:07PM	Cerus: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces First Quarter 2025 Financial Results (Business Wire)
Apr-17-25 08:30AM	Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 (Business Wire)
Mar-06-25 11:44AM	Cerus secures CE mark approval for LED-based illumination device (Medical Device Network)
Mar-05-25 01:00PM	Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) (Business Wire)
Feb-21-25 02:14AM	Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow (GuruFocus.com) -5.17%
Feb-20-25 04:20PM	Cerus: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results (Business Wire)
09:27AM	What To Expect From Cerus Corp (CERS) Q4 2024 Earnings (GuruFocus.com)
Feb-19-25 04:00PM	Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference (Business Wire)
08:30AM	Loading…
Feb-07-25 08:30AM	Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 (Business Wire)
Jan-13-25 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update (Business Wire) +5.70%
Nov-13-24 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 02:11PM	Q3 2024 Cerus Corp Earnings Call (Thomson Reuters StreetEvents) -8.72%
05:01AM	Cerus Corp (CERS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-30-24 05:10PM	Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Third Quarter 2024 Financial Results (Business Wire)
Oct-29-24 09:16AM	Cerus Corp (CERS) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-18-24 08:30AM	Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024 (Business Wire)
08:30AM	Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting (Business Wire)
08:25AM	Cerus price target lowered to $3 from $6 at Stifel (TipRanks)
Oct-16-24 04:00PM	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe (Business Wire) -9.44%
Oct-09-24 03:49PM	Cerus Corp (CERS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive EBITDA (GuruFocus.com) +8.72%
Sep-06-24 01:47AM	Insider Selling: CFO Kevin Green Sells 82,657 Shares of Cerus Corp (CERS) (GuruFocus.com)
05:10PM	Loading…
Aug-01-24 05:10PM	Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.73% +14.95%
04:07PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range (Business Wire)
Jul-18-24 08:30AM	Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire) -6.36%
Jul-02-24 04:00PM	Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors (Business Wire)
Jun-21-24 08:30AM	Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion (Business Wire)
Jun-14-24 08:30AM	Cerus Corporation Celebrates World Blood Donor Day 2024 (Business Wire)
May-22-24 08:30AM	Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference (Business Wire)
May-03-24 10:40AM	Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript (Insider Monkey) -7.95%
06:48AM	Q1 2024 Cerus Corp Earnings Call (Thomson Reuters StreetEvents)
03:58AM	Cerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-02-24 08:59PM	CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:04PM	Cerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
04:04PM	Cerus: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces First Quarter 2024 Financial Results (Business Wire)
Apr-18-24 08:30AM	Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Mar-26-24 08:30AM	Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets Doubling Previous Shelf Life (Business Wire)
Mar-19-24 08:00AM	Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients (Business Wire) +9.68%
Mar-15-24 01:49AM	Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS) (GuruFocus.com)
01:48AM	Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS) (GuruFocus.com)
Mar-07-24 01:40PM	Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven (GuruFocus.com)
11:46AM	Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 06:23AM	Q4 2023 Cerus Corp Earnings Call (Thomson Reuters StreetEvents) +21.61%
Mar-05-24 09:53PM	CERS Stock Earnings: Cerus Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.13%
04:26PM	Cerus: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-20-24 08:30AM	Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024 (Business Wire)
Feb-01-24 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire) +8.84%
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-08-24 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update (Business Wire) +5.61%
Nov-03-23 09:19AM	Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call Transcript (Insider Monkey) +8.81%
08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Nov-02-23 06:43PM	Cerus Corp (CERS) Q3 2023 Earnings: Product Revenue Stable, Operating Expenses Decrease by 4% (GuruFocus.com) +15.22%
05:25PM	Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-19-23 08:30AM	Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-10-23 08:30AM	Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting (Business Wire) +8.02%
Sep-27-23 08:30AM	Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer (Business Wire)
Sep-12-23 08:30AM	Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire)
Aug-02-23 05:15PM	Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -17.98%
04:11PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 12:36PM	Cerus (NASDAQ:CERS) investors are sitting on a loss of 60% if they invested three years ago (Simply Wall St.)
Jul-19-23 08:30AM	Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) +5.42%
Jul-03-23 05:13PM	12 Best NASDAQ Penny Stocks to Buy (Insider Monkey) -7.76%
Jun-15-23 08:30AM	Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress (Business Wire)
Jun-14-23 08:30AM	Cerus Corporation Celebrates World Blood Donor Day 2023 (Business Wire)
Jun-07-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jun-05-23 08:30AM	Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate (Business Wire)
May-30-23 07:16AM	With 72% institutional ownership, Cerus Corporation (NASDAQ:CERS) is a favorite amongst the big guns (Simply Wall St.) +5.70%
May-04-23 05:15PM	Cerus (CERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:10PM	Cerus: Q1 Earnings Snapshot (AP Finance)
04:00PM	Cerus Corporation Announces First Quarter 2023 Financial Results (Business Wire)
May-02-23 12:25PM	7 Best Cathie Wood Stocks for Your May 2023 Buy List (InvestorPlace) -8.09%
Apr-20-23 08:30AM	Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023 (Business Wire) -5.84%
Apr-18-23 10:54AM	Cerus Corporation (NASDAQ:CERS) Might Not Be As Mispriced As It Looks (Simply Wall St.)
Mar-10-23 09:24AM	Too Cheap to Ignore: Cathie Wood Snaps Up These 2 Stocks Under $10 (TipRanks)
Mar-09-23 11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Feb-28-23 04:00PM	Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results (Business Wire) -7.34%
Feb-21-23 11:00AM	Cerus (NASDAQ:CERS) shareholders have endured a 43% loss from investing in the stock a year ago (Simply Wall St.) -8.00%
Feb-15-23 08:30AM	Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023 (Business Wire)
Feb-10-23 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Jan-19-23 11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jan-09-23 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update (Business Wire) -28.04%
Dec-21-22 05:50AM	Cerus Corporation's (NASDAQ:CERS) recent 9.2% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.) +7.83%
Nov-09-22 05:58AM	Cerus Third Quarter 2022 Earnings: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021) (Simply Wall St.)
Nov-04-22 08:00AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire) +11.24%
Nov-03-22 05:55PM	Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jensen Chrystal	Chief Legal Officer	Mar 14 '25	Sale	1.45	30,075	43,609	783,294	Mar 17 05:02 PM
Jensen Chrystal	Chief Legal Officer	Mar 13 '25	Sale	1.45	18,949	27,476	813,369	Mar 17 05:02 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 14 '25	Sale	1.45	46,004	66,706	1,431,326	Mar 17 05:01 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 13 '25	Sale	1.45	29,985	43,478	1,477,330	Mar 17 05:01 PM
Greenman William Mariner	President and CEO	Mar 14 '25	Sale	1.45	122,827	178,099	4,115,845	Mar 17 05:00 PM
Greenman William Mariner	President and CEO	Mar 13 '25	Sale	1.45	71,086	103,075	4,238,672	Mar 17 05:00 PM
Green Kevin Dennis	Chief Financial Officer	Mar 14 '25	Sale	1.45	36,740	53,273	875,867	Mar 17 04:56 PM
Green Kevin Dennis	Chief Financial Officer	Mar 13 '25	Sale	1.45	23,147	33,563	912,607	Mar 17 04:56 PM
Benjamin Richard J	Chief Medical Officer	Mar 14 '25	Sale	1.45	30,075	43,609	685,775	Mar 17 04:55 PM
Benjamin Richard J	Chief Medical Officer	Mar 13 '25	Sale	1.45	18,949	27,476	715,850	Mar 17 04:55 PM
Jensen Chrystal	Chief Legal Officer	Mar 07 '25	Sale	1.50	27,457	41,131	832,318	Mar 10 07:59 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 07 '25	Sale	1.50	33,999	50,931	1,507,315	Mar 10 07:56 PM
Greenman William Mariner	President and CEO	Mar 07 '25	Sale	1.50	60,984	91,354	4,309,758	Mar 10 07:55 PM
Green Kevin Dennis	Chief Financial Officer	Mar 07 '25	Sale	1.50	31,148	46,660	935,754	Mar 10 07:54 PM
Benjamin Richard J	Chief Medical Officer	Mar 07 '25	Sale	1.50	26,139	39,156	734,799	Mar 10 07:53 PM
Jensen Chrystal	Chief Legal Officer	Mar 04 '25	Sale	1.58	66,292	104,885	405,198	Mar 05 08:31 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 04 '25	Sale	1.55	10,780	16,693	905,828	Mar 05 08:30 PM
Greenman William Mariner	President and CEO	Mar 04 '25	Sale	1.55	23,023	35,651	3,230,000	Mar 05 08:29 PM
Green Kevin Dennis	Chief Financial Officer	Mar 03 '25	Sale	1.58	60,656	95,673	493,862	Mar 05 08:27 PM
Green Kevin Dennis	Chief Financial Officer	Mar 04 '25	Sale	1.55	8,386	12,986	554,518	Mar 05 08:27 PM
Benjamin Richard J	Chief Medical Officer	Mar 03 '25	Sale	1.58	51,254	80,828	400,665	Mar 05 08:23 PM
Benjamin Richard J	Chief Medical Officer	Mar 04 '25	Sale	1.55	6,292	9,743	394,373	Mar 05 08:23 PM
Jensen Chrystal	Officer	Mar 04 '25	Proposed Sale	1.50	60,000	90,000		Mar 04 04:55 PM
RICHARD J BENJAMIN	Officer	Mar 03 '25	Proposed Sale	1.58	51,254	80,822		Mar 03 05:22 PM
KEVIN D GREEN	Officer	Mar 03 '25	Proposed Sale	1.58	60,656	95,646		Mar 03 04:56 PM
Gregory Dean A.	Director	Dec 13 '24	Buy	1.70	1,725	2,932	61,725	Jan 02 05:46 PM
BJERKHOLT ERIC	Director	Dec 12 '24	Sale	1.78	20,000	35,700	162,133	Dec 16 08:37 PM
Jensen Chrystal	Chief Legal Officer	Dec 16 '24	Sale	1.71	16,667	28,501	457,578	Dec 16 08:34 PM
CHRYSTAL NIKOLE JENSEN	Officer	Dec 16 '24	Proposed Sale	1.72	16,667	28,626		Dec 16 04:17 PM
BJERKHOLT ERIC	Director	Dec 12 '24	Proposed Sale	1.78	20,000	35,700		Dec 12 04:41 PM
Green Kevin Dennis	Chief Financial Officer	Sep 04 '24	Sale	2.15	54,272	116,826	536,093	Sep 05 05:05 PM
Green Kevin Dennis	Chief Financial Officer	Sep 03 '24	Sale	2.18	28,385	61,919	590,365	Sep 05 05:05 PM
KEVIN D GREEN	Officer	Sep 04 '24	Proposed Sale	2.15	54,272	116,826		Sep 04 04:14 PM
KEVIN D GREEN	Officer	Sep 03 '24	Proposed Sale	2.18	28,385	61,919		Sep 03 04:28 PM
Jensen Chrystal	Chief Legal Officer	Aug 15 '24	Sale	2.06	16,667	34,417	474,245	Aug 19 04:35 PM
CHRYSTAL NIKOLE JENSEN	Officer	Aug 15 '24	Proposed Sale	2.07	16,667	34,427		Aug 15 04:41 PM
Benjamin Richard J	Chief Medical Officer	Aug 02 '24	Sale	2.50	21,605	54,012	438,007	Aug 07 04:07 PM
RICHARD J BENJAMIN	Officer	Aug 02 '24	Proposed Sale	2.50	21,605	54,012		Aug 02 04:09 PM

Dollar change +1.73
Percentage change 3.87	%

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	19.00%	Shs Outstand	49.45M	Perf Week	4.32%
Market Cap	2.30B	Forward P/E	-	EPS next Y	-0.49	Insider Trans	-2.01%	Shs Float	40.12M	Perf Month	12.52%
Income	-77.34M	PEG	-	EPS next Q	-0.33	Inst Own	93.50%	Short Float	15.67%	Perf Quarter	6.72%
Sales	379.25M	P/S	6.06	EPS this Y	39.83%	Inst Trans	1.80%	Short Ratio	14.42	Perf Half Y	1.74%
Book/sh	4.72	P/B	9.83	EPS next Y	56.25%	ROA	-11.52%	Short Interest	6.29M	Perf Year	79.84%
Cash/sh	5.61	P/C	8.27	EPS next 5Y	-	ROE	-33.06%	52W Range	24.07 - 54.23	Perf YTD	12.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.14%	ROI	-14.09%	52W High	-14.48%	Beta	0.95
Dividend TTM	-	Quick Ratio	3.04	Sales past 5Y	-	Gross Margin	76.99%	52W Low	92.69%	ATR (14)	1.57
Dividend Ex-Date	-	Current Ratio	3.22	EPS Y/Y TTM	57.12%	Oper. Margin	-20.12%	RSI (14)	61.17	Volatility	2.50% 1.77%
Employees	322	Debt/Eq	1.36	Sales Y/Y TTM	69.31%	Profit Margin	-20.39%	Recom	1.10	Target Price	68.60
Option/Short	Yes / Yes	LT Debt/Eq	1.35	EPS Q/Q	44.27%	Payout	-	Rel Volume	0.63	Prev Close	44.65
Sales Surprise	13.38%	EPS Surprise	9.06%	Sales Q/Q	61.20%	Earnings	May 07 AMC	Avg Volume	436.09K	Price	46.38
SMA20	3.60%	SMA50	7.96%	SMA200	6.75%	Trades		Volume	272,949	Change	3.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
06:45PM	Loading…
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
05:15PM	Loading…
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)
07:31AM	Mirum drug for rare genetic disease gains FDA approval (BioPharma Dive)
Feb-19-25 04:04PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 (Business Wire)
Feb-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-24-25 12:00PM	Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-14-25 08:50AM	Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates (Business Wire) +6.49%
Jan-10-25 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-25 04:04PM	Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? (Zacks)
Dec-10-24 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-06-24 06:46AM	Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities (TipRanks)
Nov-14-24 08:00AM	Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire) +5.33%
Nov-13-24 02:09AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Nov-12-24 09:15AM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-08-24 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 04:30PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-24 04:30PM	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (Business Wire)
Oct-31-24 10:02AM	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Oct-23-24 08:49AM	Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth (Insider Monkey)
Oct-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis (Business Wire)
Oct-09-24 05:18PM	Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-24 08:00AM	Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies (Business Wire) +27.31%
Jun-16-24 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 (Business Wire)
Jun-10-24 10:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report? (Zacks)
Jun-06-24 09:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress (Business Wire) -5.10%
Jun-05-24 04:05PM	Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-03-24 06:46AM	EMA CHMP endorses Mirum Pharmaceuticals LIVMARLI for PFIC (Pharmaceutical Technology) +5.49%
May-31-24 08:30AM	Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older (Business Wire)
May-29-24 08:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress (Business Wire)
May-28-24 10:02AM	Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns (Zacks)
May-18-24 07:00AM	Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting (Business Wire)
May-13-24 09:40AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:55PM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss (GuruFocus.com)
01:12PM	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating (MT Newswires)
May-09-24 11:46AM	Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
07:40AM	Q1 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:49AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ... (GuruFocus.com)
May-08-24 04:02PM	Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM
Radovich Peter	PRESIDENT AND COO	Feb 03 '25	Sale	48.22	2,627	126,681	26,961	Feb 04 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	48.22	9,102	438,921	115,920	Feb 04 05:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 03 '25	Sale	48.22	1,064	51,309	4,232	Feb 04 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 24 '25	Sale	47.92	3,177	152,256	29,588	Jan 27 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 24 '25	Sale	47.92	902	43,228	3,524	Jan 27 04:48 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 24 '25	Sale	47.92	6,837	327,658	125,022	Jan 27 04:48 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 17 '25	Sale	45.86	6,969	319,598	5,649	Jan 21 04:21 PM
Radovich Peter	PRESIDENT AND COO	Jan 07 '25	Sale	42.82	1,998	85,545	27,015	Jan 08 04:44 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	42.82	7,489	320,644	119,359	Jan 08 04:42 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 07 '25	Sale	42.82	750	32,111	2,926	Jan 08 04:38 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Option Exercise	2.94	2,500	7,350	4,926	Nov 15 05:34 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Sale	47.10	2,500	117,752	2,426	Nov 15 05:34 PM
Heron Patrick J	Director	Sep 18 '24	Buy	37.40	115	4,301	162,308	Sep 20 04:39 PM
Heron Patrick J	Director	Sep 06 '24	Buy	41.58	230	9,563	162,193	Sep 10 05:04 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.94	34,013	99,862	126,783	Jul 24 05:32 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '24	Sale	34.00	375	12,750	2,426	Jul 03 06:19 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Option Exercise	2.94	30,559	89,721	57,965	Jun 25 05:15 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Sale	34.00	30,559	1,039,006	27,406	Jun 25 05:15 PM

CERS

Cerus Corp

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience